TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01423656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 29102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator: LEO 29102 vehicle
Study: NCT03074773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.~The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound
Description: The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: it is an amino amide local anesthetic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: it is an amino amide local anesthetic drug

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isotonic saline
Description: sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
Study: NCT02718508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eParenting
Description: The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
Study: NCT01874067

Intervention type: DEVICE
Intervention: Arthritis glove
Description: Isotoner three-quarter finger arthritis glove
Study: NCT02870179

Intervention type: DEVICE
Intervention: Pulse Oximeter
Description: Measurement of physiological parameters
Study: NCT04935970

Intervention type: DIAGNOSTIC_TEST
Intervention: neuropsychological test
Description: neuropsychological test, including tas-26 scale, Beck's Depression Inventory, Spielberg-Hanin'scale.
Study: NCT02275910

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7090
Study: NCT01664156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Korean red ginseng
Description: Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01641718

Intervention type: DRUG
Group type: OTHER
Intervention: Tissue glue
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.

Intervention type: DRUG
Group type: OTHER
Intervention: Tissue glue
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue glue
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.

Intervention type: DEVICE
Group type: OTHER
Intervention: Staples
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.

Intervention type: DEVICE
Group type: OTHER
Intervention: Staples
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Staples
Description: The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
Study: NCT00090610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin~For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.~Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel
Study: NCT02620150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: 10 week trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 week trial
Study: NCT03529461

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive positive pressure ventilation through nasal mask
Description: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly
Study: NCT03688685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAD-1883
Description: Treatment groups receiving twice-daily oral dosing of CAD-1883 for a treatment period of 14 days.
Study: NCT02783417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength Training
Description: G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).~G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion.
Study: NCT03529461

Intervention type: DEVICE
Group type: OTHER
Intervention: Rescue non-invasive positive pressure ventilation through nasal mask
Description: If desaturation below 90 %, nasal cannula removed and non invasive positive pressure nasal mask connected to machine: Inspiratory pressure 12 cm H2O/Expiratory pressure 6 cm H2O which can be increased to meet a tidal volume (TV) of 300-800 mL (target is 450-500), with maximum Inspiratory pressure 18 cm H2O /Expiratory pressure 8 cm H2O on 100% FiO2.If TVs are more or less than 300 to 800 mL range, the pressure will be adjusted by 1-2 cm H2O) accordingly

Intervention type: OTHER
Group type: OTHER
Intervention: Secondary rescue maneuvers
Description: If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondary rescue maneuvers
Description: If rescue non invasive positive pressure maneuver attempted (including adjustments in pressure) and O2 sat is not above 90 % within 3 min of starting non invasive positive pressure, scope removed and secondary rescue maneuver started. Secondary rescue maneuvers performed at the discretion of the anesthesiologist (chin lift, oral airway, bag mask, nasal trumpet, LMA, intubation). If sat \> 90 % with secondary rescue maneuvers, resumption of scope exam to the discretion of anesthesia. If sat does not increase \> 90 % with secondary rescue maneuvers, scope exam to be cancelled and patient care per anesthesiologist
Study: NCT03516253

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil + EPO
Description: Supplementation with both fish oil and EPO
Study: NCT00152178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur) and tamoxifen
Description: UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen
Description: CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
Study: NCT03690661

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Video Game
Description: The intervention game employs evidence-based serious game mechanics (e.g., storylines, long-term goals, scaling difficulty) to design a learning environment that maximizes opportunities for adolescents with ASD to discover the functional utility of eye gaze cues.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Game
Description: The placebo game will have all the elements of the serious game mechanics of the intervention game (narrative storylines, long-term goals, scaling difficulty), but will not provide the learning opportunities regarding eye gaze cues.
Study: NCT02188914

Intervention type: RADIATION
Intervention: Positron emission tomography scan

Intervention type: RADIATION
Intervention: Positron emission tomography scan

Intervention type: OTHER
Intervention: Magnetic resonance imaging

Intervention type: OTHER
Intervention: Magnetic resonance imaging
Study: NCT02161250

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant Starch
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
Study: NCT00548951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snoezelen Room
Description: Session in a Snoezelen room once per week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Snoezelen Room
Description: Session in a Snoezelen room three times per week for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Receive no sessions in a Snoezelen Room.
Study: NCT01752543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan
Description: Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Dextrose)
Description: Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
Study: NCT03158974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: East Indian Sandalwood Oil Cream
Description: Cream containing 10% East Indian Sandalwood Oil (EISO)/Albuterpenoids
Study: NCT01379001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM or PO placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IM or PO placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: donepezil 5mg PO x 1
Study: NCT00813566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with metabolic imaging tracer that aids in assessment, diagnosis, and staging of patients with cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]fluorothymidine (FLT)
Description: Brain scan with a radiolabeled imaging agent for investigating cellular proliferation of tumors

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [15O]-H2O
Description: Brain scan with imaging agent to determine tumor blood flow

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]Acetate
Description: Brain scan with imaging agent to determine growth activity of tumor
Study: NCT03938714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrhoidectomy
Description: Excision of third and fourth degree hemorrhoids

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemorrhoidectomy
Description: Excision of third and fourth degree hemorrhoids
Study: NCT03862066

Intervention type: OTHER
Intervention: Blood collection
Description: 5 milliliters (mL) of blood will be collected at the time of surgery

Intervention type: OTHER
Intervention: Blood collection
Description: 5 milliliters (mL) of blood will be collected at the time of surgery

Intervention type: OTHER
Intervention: Tissue collection
Description: Left over tissue will be collected at the time of surgery

Intervention type: OTHER
Intervention: Tissue collection
Description: Left over tissue will be collected at the time of surgery
Study: NCT02317614

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SteadyRx
Description: The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
Study: NCT05937828

Intervention type: OTHER
Intervention: data collection
Description: description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.

Intervention type: OTHER
Intervention: data collection
Description: description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.

Intervention type: OTHER
Intervention: data collection
Description: description of the long-term health of adult patients, identification of the heterogenous genetic underlying pathophysiologic contexts, study of the benefit-risk balance of treatments, including the growing development of targeted therapies.
Study: NCT00631449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
Study: NCT01777360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALAIR, radiofrequency catheter for bronchial THERMOPLASTY
Description: radiofrequency catheter for bronchial THERMOPLASTY
Study: NCT01108406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonitus SoundBite System
Description: Non Surgical Bone Conduction Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SoundBite Hearing System
Study: NCT03301623

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support
Description: The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Education and Activation Tools
Description: The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication).
Study: NCT02981303

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imprime PGG
Description: Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
Study: NCT00266396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommend full weight-bearing
Description: The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recommend parital weight-bearing
Description: The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg